AU2021900532A0 - Synthetic method - Google Patents

Synthetic method

Info

Publication number
AU2021900532A0
AU2021900532A0 AU2021900532A AU2021900532A AU2021900532A0 AU 2021900532 A0 AU2021900532 A0 AU 2021900532A0 AU 2021900532 A AU2021900532 A AU 2021900532A AU 2021900532 A AU2021900532 A AU 2021900532A AU 2021900532 A0 AU2021900532 A0 AU 2021900532A0
Authority
AU
Australia
Prior art keywords
synthetic method
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021900532A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telix International Pty Ltd
Original Assignee
Telix International Pty Ltd
Filing date
Publication date
Application filed by Telix International Pty Ltd filed Critical Telix International Pty Ltd
Publication of AU2021900532A0 publication Critical patent/AU2021900532A0/en
Priority to MX2023010017A priority Critical patent/MX2023010017A/en
Priority to JP2023552249A priority patent/JP2024512283A/en
Priority to CA3208892A priority patent/CA3208892A1/en
Priority to US18/547,286 priority patent/US20240082435A1/en
Priority to PCT/AU2022/050154 priority patent/WO2022178592A1/en
Priority to AU2022227439A priority patent/AU2022227439A1/en
Priority to BR112023017157A priority patent/BR112023017157A2/en
Priority to KR1020237033414A priority patent/KR20230155494A/en
Priority to EP22758645.0A priority patent/EP4297804A1/en
Pending legal-status Critical Current

Links

AU2021900532A 2021-02-26 2021-02-26 Synthetic method Pending AU2021900532A0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2023010017A MX2023010017A (en) 2021-02-26 2022-02-25 Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents.
JP2023552249A JP2024512283A (en) 2021-02-26 2022-02-25 Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents
CA3208892A CA3208892A1 (en) 2021-02-26 2022-02-25 Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agent
US18/547,286 US20240082435A1 (en) 2021-02-26 2022-02-25 Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents
PCT/AU2022/050154 WO2022178592A1 (en) 2021-02-26 2022-02-25 Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents
AU2022227439A AU2022227439A1 (en) 2021-02-26 2022-02-25 Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents
BR112023017157A BR112023017157A2 (en) 2021-02-26 2022-02-25 Solid-phase synthesis of prostate-specific membrane antigen (psma)-targeting conjugates derived from glutamate-urea-lysine (gul-derivatives) and their use as precursors of therapeutic and/or diagnostic agents
KR1020237033414A KR20230155494A (en) 2021-02-26 2022-02-25 Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents.
EP22758645.0A EP4297804A1 (en) 2021-02-26 2022-02-25 Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents

Publications (1)

Publication Number Publication Date
AU2021900532A0 true AU2021900532A0 (en) 2021-03-18

Family

ID=

Similar Documents

Publication Publication Date Title
EP4106516A4 (en) Grow method
EP3925954A4 (en) Fluorolactone and method for producing same
EP4001251A4 (en) Method for producing binaphthyls
EP4109493A4 (en) Bacteriostatic method
EP4046687A4 (en) Method for producing centanafadine
EP3971222A4 (en) Complex compound and production method therefor
EP4082997A4 (en) Alkene manufacturing method
EP3950951A4 (en) Method for preparing toxin
EP3911764A4 (en) Screening method
EP3868763A4 (en) Compound and method for producing same
EP3808853A4 (en) Selenoneine production method
AU2022298331A9 (en) Methods
EP4036245A4 (en) Lipopolysaccharide production method
EP3943659A4 (en) Method for manufacturing synthetic leather
EP3981754A4 (en) Method for manufacturing 1-halo-2-fluoroethylene
EP3971173A4 (en) Fluorolactone and method for producing same
EP4011855A4 (en) Olefin compound production method
EP3832540A4 (en) Product positioning method
AU2021903428A0 (en) Synthetic method
AU2021900532A0 (en) Synthetic method
EP4037892A4 (en) Object decaking
AU2021900739A0 (en) Method
AU2020901794A0 (en) Method
AU2020900337A0 (en) Method
AU2021901926A0 (en) Methods